{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:34:16Z","timestamp":1781145256651,"version":"3.54.1"},"reference-count":41,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,8,5]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy. Topics of special interest included infections and cardiovascular and thromboembolic events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This analysis included integrated safety data from three randomised, placebo-controlled studies (one phase 2 and two phase 3) and one long-term extension study. Data are reported in three data sets: placebo-controlled, extended exposure and all-baricitinib. Outcomes include treatment-emergent adverse events (AEs), AEs of special interest and abnormal laboratory changes. Proportions of patients with events and incidence rates (IRs) were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1655 patients received baricitinib for up to 3.5 years (median duration 473 days). With baricitinib 4\u2009mg, baricitinib 2\u2009mg and placebo, respectively, 50.8%, 50.7% and 49.0% of patients reported at least one infection and 4.4%, 3.4% and 1.9% of patients had a serious infection. The most common treatment-emergent infections included urinary tract infection, COVID-19, upper respiratory tract infection and nasopharyngitis. Herpes zoster was more common with baricitinib 4\u2009mg (4.7%) vs baricitinib 2\u2009mg (2.7%) and placebo (2.8%). Among baricitinib-4 mg, 2\u2009mg and placebo-treated patients, respectively, 4 (IR=0.9), 1 (IR=0.2) and 0 experienced at least one positively adjudicated major adverse cardiovascular event, and 0, 3 (IR=0.6) and 2 (IR=0.4) reported at least one positively adjudicated venous thromboembolism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results of this integrated safety analysis in patients with SLE are not substantially different to the established safety profile of baricitinib. No increased venous thromboembolism was found.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003302","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T12:36:33Z","timestamp":1692621393000},"page":"e003302","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct02708095","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03616912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03616964","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03843125","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02708095","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03616912","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03616964","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03843125","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric","family":"Morand","sequence":"first","affiliation":[{"name":"Centre for Inflammatory Disease, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"University of Occupational and Environmental Health, Japan, Kitakyushu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Silk","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dickson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Meszaros","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Issa","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"TechData Service, King of Prussia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charite Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Deutsches Rheumaforschungszentrum, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,21]]},"reference":[{"key":"2025090312024189000_9.3.e003302.1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"2025090312024189000_9.3.e003302.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.186"},{"key":"2025090312024189000_9.3.e003302.3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.berh.2017.09.012","article-title":"Atherosclerosis in systemic lupus erythematosus","volume":"31","author":"Croca","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025090312024189000_9.3.e003302.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/25785826.2019.1628466","article-title":"Systemic lupus erythematosus and immunodeficiency","volume":"42","author":"Sawada","year":"2019","journal-title":"Immunol Med"},{"key":"2025090312024189000_9.3.e003302.5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/1535370218824547","article-title":"IL-12 and IL-23\/Th17 axis in systemic lupus erythematosus","volume":"244","author":"Larosa","year":"2019","journal-title":"Exp Biol Med (Maywood)"},{"key":"2025090312024189000_9.3.e003302.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60954-X"},{"key":"2025090312024189000_9.3.e003302.7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/art.39950","article-title":"Gene expression and pharmacodynamic changes in 1,760 systemic lupus erythematosus patients from two phase III trials of BAFF blockade with tabalumab","volume":"69","author":"Hoffman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312024189000_9.3.e003302.8","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2025090312024189000_9.3.e003302.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025090312024189000_9.3.e003302.10","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial Implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2025090312024189000_9.3.e003302.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1"},{"key":"2025090312024189000_9.3.e003302.12","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"2025090312024189000_9.3.e003302.13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"2025090312024189000_9.3.e003302.14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/imm.13103","article-title":"Infectious processes and systemic lupus erythematosus","volume":"158","author":"Illescas-Montes","year":"2019","journal-title":"Immunology"},{"key":"2025090312024189000_9.3.e003302.15","article-title":"Vascular disease in systemic lupus erythematosus","volume":"2012","author":"Pyrpasopoulou","year":"2012","journal-title":"Autoimmune Dis"},{"key":"2025090312024189000_9.3.e003302.16","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500285352"},{"key":"2025090312024189000_9.3.e003302.17","doi-asserted-by":"crossref","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2025090312024189000_9.3.e003302.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb05705.x"},{"key":"2025090312024189000_9.3.e003302.19","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1007\/s12325-022-02281-4","article-title":"A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19","volume":"39","author":"Bieber","year":"2022","journal-title":"Adv Ther"},{"key":"2025090312024189000_9.3.e003302.20","doi-asserted-by":"publisher","DOI":"10.1002\/art.22924"},{"key":"2025090312024189000_9.3.e003302.21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jaut.2016.10.004","article-title":"The antiphospholipid syndrome in patients with systemic lupus erythematosus","volume":"76","author":"Pons-Estel","year":"2017","journal-title":"J Autoimmun"},{"key":"2025090312024189000_9.3.e003302.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30237-5"},{"key":"2025090312024189000_9.3.e003302.23","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trsl.2020.12.007","article-title":"COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease","volume":"232","author":"Fernandez-Ruiz","year":"2021","journal-title":"Transl Res"},{"key":"2025090312024189000_9.3.e003302.24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.589474","article-title":"COVID-19 and systemic lupus erythematosus: focus on immune response and therapeutics","volume":"11","author":"Spihlman","year":"2020","journal-title":"Front Immunol"},{"key":"2025090312024189000_9.3.e003302.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221276"},{"key":"2025090312024189000_9.3.e003302.26","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/keaa478","article-title":"The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis","volume":"60","author":"Pego-Reigosa","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090312024189000_9.3.e003302.27","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313493032"},{"key":"2025090312024189000_9.3.e003302.28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312024189000_9.3.e003302.29","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2022.2039122","article-title":"Recent issues in JAK inhibitor safety: perspective for the clinician","volume":"18","author":"Fleischmann","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312024189000_9.3.e003302.30","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7025329","article-title":"Systemic lupus erythematosus, its impact on selected cardiovascular risk factors, and correlation with duration of illness: a pilot study","volume":"2020","author":"Przywara-Chowaniec","year":"2020","journal-title":"Cardiol Res Pract"},{"key":"2025090312024189000_9.3.e003302.31","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/acr.23018","article-title":"Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study","volume":"69","author":"Avi\u00f1a-Zubieta","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312024189000_9.3.e003302.32","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/art.40174","article-title":"Race\/ethnicity and cardiovascular events among patients with systemic lupus erythematosus","volume":"69","author":"Barbhaiya","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025090312024189000_9.3.e003302.33","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12518"},{"key":"2025090312024189000_9.3.e003302.34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.071244"},{"key":"2025090312024189000_9.3.e003302.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.10.012"},{"key":"2025090312024189000_9.3.e003302.36","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"2025090312024189000_9.3.e003302.37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/1744666X.2022.2039630","article-title":"Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events","volume":"18","author":"Atzeni","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090312024189000_9.3.e003302.38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000511759","article-title":"Hematological manifestations among patients with rheumatic diseases","volume":"144","author":"Klein","year":"2021","journal-title":"Acta Haematol"},{"key":"2025090312024189000_9.3.e003302.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218510"},{"key":"2025090312024189000_9.3.e003302.40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2025090312024189000_9.3.e003302.41","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001370","article-title":"Changes in selected haematological parameters associated with JAK1\/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib","volume":"6","author":"Kay","year":"2020","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:02:51Z","timestamp":1756926171000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,8,21]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/rmdopen-2023-003302"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003302","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}